Cybrexa Therapeutics
Jane Bechtold has a diverse work experience spanning over several years. Jane worked as a Senior Associate Research Scientist at Bayer from 1994 to 2002, designing and validating assays in the high throughput screening unit to test Bayer's compound library for potential therapeutic activity. In 2011, they worked at Helix Therapeutics as an Associate Research Scientist for four months. In 2015, Jane worked as a Document Reviewer at Advanced Clinical Perspectives and reviewed reports such as clinical study reports, clinical protocols, and summaries of changes, among others. Jane also completed the AMWA Essential Skills Certification in 2016 and was a member of the American Medical Writers Association (AMWA). From 2015 to 2017, Jane also worked at Madison Public Schools as a Special Education Paraprofessional. Their recent work experience includes working as a Research Scientist at Cybrexa Therapeutics from 2017 to 2022 and as an Alliance Management professional at Biohaven Pharmaceuticals in 2022. Currently, they are working as a Laboratory Manager at Cybrexa Therapeutics since March 2023.
Jane Bechtold received a Master's degree in Medical Microbiology and Bacteriology from Creighton University. Jane attended the university from 1987 to 2000.
This person is not in any teams
Cybrexa Therapeutics
1 followers
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and itwill greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.